Detail akcie China Shineway Pharmaceutical Group Ltd, Ordinary, Frankfurt Stock Exchange online

Business Summary: China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, China Shineway Pharmaceutical Group Ltd revenues decreased 16% to RMB3.78B. Net income decreased 13% to RMB840.1M. Revenues reflect Injections segment decrease of 29% to RMB1.27B, TCM formula granules segment decrease of 9% to RMB1.09B. Net income also reflects Net exchange (gain) loss (included in ot increase from RMB6.6M (income) to RMB55.4M (expense).